Navigation Links
Gap Introduces Inspirational Marketing Campaign to Celebrate First Anniversary of Global Launch of Gap (PRODUCT) RED
Date:10/3/2007

Anne Hathaway, John Legend and Wyclef Jean join Terrence Howard, Natalie Maines and Abigail Breslin to help launch the new (2 WEEKS) T-Shirt and

latest Gap (PRODUCT) RED collections

SAN FRANCISCO, Oct. 3 /PRNewswire-FirstCall/ -- Gap is proud to introduce its latest marketing campaign for (PRODUCT) RED, a for-benefit brand designed to help eliminate AIDS in Africa. Captured by acclaimed photographer Annie Leibovitz and featuring a diverse cast of socially-conscious celebrities, the new campaign underscores the idea that it is possible for an individual to change the world.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071003/AQW079)

"Since launching last year, (PRODUCT) RED has contributed more than $45 million to the Global Fund to finance programs that help women and children affected by HIV/AIDS in Africa," said Marka Hansen, president of Gap Brand North America. "Gap is honored to be a partner of (PRODUCT) RED and we're excited to continue creating special, limited edition collections that help raise awareness of the epidemics facing Africa, while inspiring people to make a difference in the lives of others."

Built around a theme of change, Gap's latest print campaign features celebrities photographed as individuals or together with special friends and loved ones. Each individual in the campaign wears a Gap (PRODUCT) RED item in a way that expresses their own personal style. Thought-provoking questions, such as "Can the shirt off your back change the world?" and "Can the next generation change the world?" accompany the images, helping capture the emotion and power of the individuals in the campaign. Three new celebrities appear in the campaign -- actress Anne Hathaway; Grammy Award-winning artist John Legend surrounded by the African Children's Choir; and Grammy Award-winning musician and producer Wyclef Jean embracing his daughte
'/>"/>

SOURCE Gap Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. TI Cycles Introduces Foldman
3. Canada Introduces Mandatory Nutrition Labeling
4. Amgen introduces Autoinjector For Treating Anemia
5. Cuba Introduces New Device for Detecting Vascular Diseases
6. China Introduces Solar-powered Baths
7. Allergan Introduces ‘Dermal Filler’ for Smile Lins
8. UAE Introduces Cervical Cancer Vaccine
9. Cynosure Introduces Higher Power Smartlipo(TM) LaserBodySculpting Workstation
10. Iceland Introduces Smoking Ban in Bars and Restaurants
11. Indian Introduces Paan-flavoured Condoms
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3AMD LASERS Announces Partnerships With Three Industry Leading Companies 5686 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 1Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 2Keryx Biopharmaceuticals Inc Announces Upcoming Poster Presentation of Zerenex 28ferric citrate 29 for the Treatment of Hyperphosphatemia at the Up 5683 3Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 1Advanced Health Media Named to Deloittes 2009 Technology Fast 500 28TM 29 5680 2